MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

Search

Supernus Pharmaceuticals Inc

Abierto

SectorSalud

48.59 0.79

Resumen

Variación precio

24h

Actual

Mínimo

47.71

Máximo

49.58

Métricas clave

By Trading Economics

Ingresos

34M

22M

Ventas

16M

165M

P/B

Media del Sector

41.391

35.739

Margen de beneficio

13.598

Empleados

674

EBITDA

20M

38M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

-0.6% downside

Dividendos

By Dow Jones

Próximas Ganancias

3 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

594M

2.7B

Apertura anterior

47.8

Cierre anterior

48.59

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

149 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Supernus Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

2 oct 2025, 23:30 UTC

Acciones populares

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 oct 2025, 21:21 UTC

Ganancias

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 oct 2025, 00:00 UTC

Adquisiciones, fusiones, absorciones

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 oct 2025, 23:40 UTC

Charlas de Mercado

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 oct 2025, 23:39 UTC

Charlas de Mercado

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 oct 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 oct 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 oct 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 oct 2025, 23:00 UTC

Charlas de Mercado

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 oct 2025, 22:54 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Scales's JV Buyout Lauded by Bull -- Market Talk

2 oct 2025, 22:54 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Forex and Fixed Income Roundup: Market Talk

2 oct 2025, 22:46 UTC

Charlas de Mercado

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 oct 2025, 22:46 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 oct 2025, 21:17 UTC

Adquisiciones, fusiones, absorciones

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 oct 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Energy & Utilities Roundup: Market Talk

2 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

2 oct 2025, 20:49 UTC

Adquisiciones, fusiones, absorciones

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 oct 2025, 20:00 UTC

Adquisiciones, fusiones, absorciones

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 oct 2025, 19:20 UTC

Charlas de Mercado

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 oct 2025, 19:10 UTC

Charlas de Mercado

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 oct 2025, 19:04 UTC

Charlas de Mercado

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 oct 2025, 18:45 UTC

Adquisiciones, fusiones, absorciones

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 oct 2025, 18:45 UTC

Adquisiciones, fusiones, absorciones

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 oct 2025, 18:44 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 oct 2025, 18:44 UTC

Adquisiciones, fusiones, absorciones

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 oct 2025, 18:44 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 oct 2025, 18:43 UTC

Adquisiciones, fusiones, absorciones

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Comparación entre iguales

Cambio de precio

Supernus Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

-0.6% caída

Estimación a 12 meses

Media 47.75 USD  -0.6%

Máximo 63 USD

Mínimo 40 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Supernus Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

31.35 / 32.36Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

149 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
help-icon Live chat